According to him, it’s non-invasive, is a single dose vaccine, will be quicker and easier to administer, will offer faster, stronger and longer immunity and last but not the least, it will also be eco-friendly.
“You just need to put one drop here (in one nostril) and another drop there (other nostril) you are done with the vaccination. We can put 20 doses in a vial and we are also looking at if we put it in dropper, there should not be any cross contamination with another individual…so we are putting other (dropper) tips… so that they can dispose of the small tip (after administering each dose). We can reach (people) faster with the nasal drop,” he had said earlier during a chat with Biocon founder Kiran Mazumdar-Shaw during the TiE global summit held late November.
Bharat Biotech is working on two intranasal vaccines—one with the University of Washington School of Medicine at St Louis (WashU) and another with USA-based vaccine maker FluGen and virologists from the University of Wisconsin-Madison, Ella’s alma mater.
Of these, the one being developed with WashU has shown extremely promising results in animal studies and is slated to begin Phase I/II human trials this month. The vaccine is expected to be ready for use by the third quarter of 2021, said sources. Bharat Biotech has already put in place a strategy to produce enough to vaccinate 500 million people with the single dose intranasal vaccine, Dr Ella had said earlier.
In fact, Ella has on multiple occasions publicly called the intranasal vaccine a gamechanger and humankind’s best bet against prevention of Covid-19 as the disease is also transmitted through the nasal route.
“The nasal vaccine is probably the ideal choice if you want to stop the infection and transmission (of Covid-19),” he said earlier this week.